Related Experiment Video
Updated: May 1, 2026
A Seminiferous Tubule Squash Technique for the Cytological Analysis of Spermatogenesis Using the Mouse Model
Published on: February 6, 2018
[Diagnostics and treatment of seminomatous germ cell tumors]
F Zengerling1, J Müller, S Krege
1Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm, Prittwitzstr. 43, 89075, Ulm, Deutschland.
Abstract:
Currently, seminomas account for about 60% of newly diagnosed testicular cancers in Germany, with an increasing trend. In lower tumor stages the main focus is on the avoidance of over therapy. This is of special interest in stage I where radiotherapy, carboplatin monotherapy and surveillance are available therapies as well as in stage IIA/B. Due to high late toxicity, radiotherapy of the retroperitoneal space is obsolete for young patients with clinical stage I and, in its present form, discussed controversially for patients with clinical stage IIA/B. The cause for this paradigm shift is the high percentage of secondary malignancies resulting after radiotherapy of the retroperitoneal space. Furthermore, 10-25% of the patients receiving radiotherapy alone for clinical stage IIA/B seminoma suffer from a relapse of the disease due to tumor recurrence in extraregional lymph nodes. Therefore, an ongoing study is investigating if a combined treatment with neoadjuvant carboplatin and radiotherapy with a limited target volume can reduce toxicity without jeopardizing the cure rate. Patients with residual tumors >3 cm should undergo 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) computed tomography scanning after a minimum interval of 6 weeks after chemotherapy. In the case of a positive FDG-PET-CT result, the further therapeutic strategy should be the subject of interdisciplinary discussions.
Insights
This study explores reducing toxicity in testicular cancer treatment by combining carboplatin chemotherapy with limited radiotherapy. The goal is to maintain high cure rates for seminoma patients while minimizing long-term side effects.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Imaging
Context:
- Seminomas represent a significant portion of testicular cancers in Germany, with a rising incidence.
- Minimizing overtreatment in early-stage testicular cancer (Stage I and IIA/B) is crucial.
- Traditional retroperitoneal radiotherapy for seminoma is associated with high late toxicity, including secondary malignancies, and a notable relapse rate.
Purpose:
- To investigate a combined neoadjuvant carboplatin and limited-volume radiotherapy approach for seminoma.
- To assess if this combined treatment can reduce toxicity without compromising efficacy.
- To establish guidelines for post-chemotherapy imaging and subsequent therapeutic decisions.
Summary:
- A study is evaluating a combined treatment of neoadjuvant carboplatin and radiotherapy with a reduced target volume for seminoma.
- This approach aims to decrease toxicity, particularly late effects and secondary malignancies, compared to traditional radiotherapy.
- 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) computed tomography is utilized for residual tumor assessment post-chemotherapy, guiding further management.
Impact:
- Potential for reduced long-term side effects in young testicular cancer patients.
- Improved therapeutic strategies for Stage I and IIA/B seminoma, balancing cure rates and quality of life.
- Informed clinical decision-making through standardized imaging protocols and interdisciplinary consultation.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
01:41Spermatogenesis